Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016
Published Aug 10, 2016
43 pages — Published Aug 10, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016, provides in depth analysis on Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted pipeline therapeutics.

The report provides comprehensive information on the Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6)
- The report reviews Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to f

  
Source:
Document ID
GMDHC0448TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Overview61
Therapeutics Development73
  Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Products under Development by Stage of Development71
  Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Products under Development by Therapy Area81
  Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Products under Development by Indication91
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Products under Development by Companies122
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Therapeutics Assessment145
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration162
  Assessment by Molecule Type181
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Companies Involved in Therapeutics Development193
  Celtaxsys, Inc.191
  Johnson &Johnson201
  Nippon Kayaku Co., Ltd.211
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Drug Profiles2210
  acebilustat Drug Profile223
  CTX-3397 Drug Profile251
  CTX-3421 Drug Profile261
  EDO-66 Drug Profile271
  JNJ-26993135 Drug Profile281
  Small Molecules to Inhibit Leukotriene B4 for Chronic Obstructive Pulmonary Disease Drug Profile291
  ubenimex Drug Profile302
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Dormant Projects321
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Featured News &Press Releases339
  Jul 25, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema331
  Jul 18, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension331
  May 03, 2016: Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis341
  Mar 28, 2016: Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency351
  Dec 15, 2015: Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension351
  Nov 30, 2015: Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary351
  Oct 08, 2015: Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis361
  Oct 01, 2015: Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients361
  Jul 06, 2015: Celtaxsys Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis371
  Jun 10, 2015: Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF381
  Jun 02, 2015: Celtaxsys Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial381
  Apr 07, 2015: Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris - Recruitment of Patients to Commence Immediately391
  Feb 03, 2015: Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA401
  Oct 30, 2014: Celtaxsys Cystic Fibrosis Therapy Receives Positive Opinion In EU401
  Oct 10, 2013: Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients411
Appendix422
  Methodology421
  Coverage421
  Secondary Research421
  Primary Research421
  Expert Panel Validation421
  Contact Us421
  Disclaimer431

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Leukotriene-A-4-Hydrolase-LTA-4-Hydrolase-or-Leukotriene-A-4-Hydrolase-or-LTA4H-or-EC-3-3-2-6-Pipeline-Review-H2-2016-2088-16371>
  
APA:
Global Markets Direct - Market Research. (2016). Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Leukotriene-A-4-Hydrolase-LTA-4-Hydrolase-or-Leukotriene-A-4-Hydrolase-or-LTA4H-or-EC-3-3-2-6-Pipeline-Review-H2-2016-2088-16371>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.